

Table of Tables

Table 1 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (no disease modifying effect)	2
Table 2 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 onward)	2
Table 3 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with PDT	3
Table 4 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with best supportive care	4
Table 5 Cumulative scenario analyses – Minimally classic and occult no classic lesions treated with ranibizumab	5

Table 1 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (no disease modifying effect)

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	8,062	0.26	30,986
“Brazier” utilities	8,062	0.21	38,928
Novartis injection cost (25% outpatient, 75% day case)	11,352	0.21	54,813
Change cost of community care (uptake = 0.17) ^a	10,895	0.21	52,604
Change cost of community care (uptake = 0.25) ^b	10,562	0.21	50,999
Notes: ^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included) ^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)			

Table 2 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 onward)

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	6,941	0.34	20,467
“Brazier” utilities	6,941	0.27	25,509
Novartis injection cost (25% outpatient, 75% day case)	10,231	0.27	37,600
Change cost of community care (uptake = 0.17) ^a	9,610	0.27	35,319
Change cost of community care (uptake = 0.25) ^b	9,159	0.27	33,661
Notes: ^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included) ^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)			

Table 3 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with PDT

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	5,391	0.34	15,638
“Brazier” utilities	5,391	0.28	19,491
Novartis injection cost (25% outpatient, 75% day case)	8,096	0.28	29,272
Change cost of community care (uptake = 0.17) ^a	7,640	0.28	27,623
Change cost of community care (uptake = 0.25) ^b	7,309	0.28	26,425
Second year of treatment, dosing as in year 1 of ANCHOR study (12 injections in year 1 and 12 in year 2) ^c	16,003	0.43	37,489
Second year of treatment, reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	5,836	0.43	13,671
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			

Table 4 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with best supportive care

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	6,457	0.57	11,412
“Brazier” utilities	6,457	0.45	14,388
Novartis injection cost (25% outpatient, 75% day case)	9,163	0.45	20,416
Change cost of community care (uptake = 0.17) ^a	8,320	0.45	18,539
Change cost of community care (uptake = 0.25) ^b	7,708	0.45	17,175
Second year of treatment, dosing as in year 1 of ANCHOR study (12 injections in year 1 and 12 in year 2) ^c	17,363	0.73	23,887
Second year of treatment, reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	7,196	0.73	9,900
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			

Table 5 Cumulative scenario analyses – Minimally classic and occult no classic lesions treated with ranibizumab

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	17,309	0.69	25,098
“Brazier” utilities	17,309	0.54	31,966
Novartis injection cost (25% outpatient, 75% day case)	22,512	0.54	41,575
Change cost of community care (uptake = 0.17) ^a	21,598	0.54	39,886
Change cost of community care (uptake = 0.25) ^b	20,933	0.54	38,659
Treatment dosing as in MARINA study (12 injections in year 1 and 12 in year 2) ^c	20,933	0.54	38,659
Reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	10,777	0.54	19,904
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			

Table of Tables

Table 1 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (no disease modifying effect)	2
Table 2 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 only)	2
Table 3 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 onward)	3
Table 4 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with PDT	4
Table 5 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with best supportive care	5
Table 6 Cumulative scenario analyses – Minimally classic and occult no classic lesions treated with ranibizumab	6

Table 1 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (no disease modifying effect)

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	8,062	0.26	30,986
“Brazier” utilities	8,062	0.21	38,928
Novartis injection cost (25% outpatient, 75% day case)	11,352	0.21	54,813
Change cost of community care (uptake = 0.17) ^a	10,895	0.21	52,604
Change cost of community care (uptake = 0.25) ^b	10,562	0.21	50,999
Notes: ^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included) ^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)			

Table 2 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 only)

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	7,710	0.29	26,896
“Brazier” utilities	7,710	0.23	33,716
Novartis injection cost (25% outpatient, 75% day case)	11,000	0.23	48,102
Change cost of community care (uptake = 0.17) ^a	10,491	0.23	45,877
Change cost of community care (uptake = 0.25) ^b	10,121	0.23	44,259
Notes: ^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included) ^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)			

Table 3 Cumulative scenario analyses – Pegaptanib-treated cohort compared with usual care (disease modifying effect, year 3 onward)

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	6,941	0.34	20,467
“Brazier” utilities	6,941	0.27	25,509
Novartis injection cost (25% outpatient, 75% day case)	10,231	0.27	37,600
Change cost of community care (uptake = 0.17) ^a	9,610	0.27	35,319
Change cost of community care (uptake = 0.25) ^b	9,159	0.27	33,661
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p>			

Table 4 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with PDT

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	5,391	0.34	15,638
“Brazier” utilities	5,391	0.28	19,491
Novartis injection cost (25% outpatient, 75% day case)	8,096	0.28	29,272
Change cost of community care (uptake = 0.17) ^a	7,640	0.28	27,623
Change cost of community care (uptake = 0.25) ^b	7,309	0.28	26,425
Second year of treatment, dosing as in year 1 of ANCHOR study (12 injections in year 1 and 12 in year 2) ^c	16,003	0.43	37,489
Second year of treatment, reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	5,836	0.43	13,671
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			

Table 5 Cumulative scenario analyses – Predominantly classic lesions treated with ranibizumab, compared with best supportive care

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	6,457	0.57	11,412
“Brazier” utilities	6,457	0.45	14,388
Novartis injection cost (25% outpatient, 75% day case)	9,163	0.45	20,416
Change cost of community care (uptake = 0.17) ^a	8,320	0.45	18,539
Change cost of community care (uptake = 0.25) ^b	7,708	0.45	17,175
Second year of treatment, dosing as in year 1 of ANCHOR study (12 injections in year 1 and 12 in year 2) ^c	17,363	0.73	23,887
Second year of treatment, reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	7,196	0.73	9,900
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			

Table 6 Cumulative scenario analyses – Minimally classic and occult no classic lesions treated with ranibizumab

Scenario	Incremental cost (£)	Incremental QALY	ICER (£/ QALY)
Base case	17,309	0.69	25,098
“Brazier” utilities	17,309	0.54	31,966
Novartis injection cost (25% outpatient, 75% day case)	22,512	0.54	41,575
Change cost of community care (uptake = 0.17) ^a	21,598	0.54	39,886
Change cost of community care (uptake = 0.25) ^b	20,933	0.54	38,659
Treatment dosing as in MARINA study (12 injections in year 1 and 12 in year 2) ^c	20,933	0.54	38,659
Reduced frequency dosing (8 injections in year 1 and 6 in year 2) ^d	10,777	0.54	19,904
<p>Notes:</p> <p>^a “Brazier” utilities, Novartis injection cost and uptake of community care at 17% (no other adjustments to costs of blindness included)</p> <p>^b “Brazier” utilities, Novartis injection cost and uptake of community care at 25% (no other adjustments to costs of blindness included)</p> <p>^c “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (24 injections, with monthly monitoring)</p> <p>^d “Brazier” utilities, Novartis injection cost, uptake of community care at 25% and two years of treatment (14 injections, with monthly monitoring)</p>			